The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.
 
Vicky Makker
Consulting or Advisory Role - Eisai
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Mark Messing
Leadership - US Oncology
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Allen Lee Cohn
Honoraria - Bristol-Myers Squibb; Ipsen; Merrimack; Roche/Genentech
Speakers' Bureau - Merrimack
 
Carol Aghajanian
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Clovis Oncology; Oxigene; Oxigene; Tesaro
 
Daniel E. Stepan
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai (Inst)
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
 
Matthew Guo
Employment - Eisai
 
Pallavi Sachdev
Employment - Eisai
 
Robert Charles Shumaker
Employment - Asubio Pharma (I); Eisai
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Trillium Therapeutics
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Onyx; Trillium Therapeutics